CKD Fibrosis Drug Landscape 2026: Approved & Pipeline Guide
CKD drug landscape 2026: Finerenone, SGLT2i, GLP-1RA plus newly approved Atrasentan, Sibeprenlimab, Iptacopan, and emerging ASIs/ERAs.
1. Renal Fibrosis and CKD Treatment: A New Era of Standard of Care
Chronic Kidney Disease (CKD) is a massive global public health challenge affecting approximately 800 million people. The ultimate common pathological pathway for CKD is Renal Fibrosis—progressive glomerulosclerosis and tubulointerstitial fibrosis that inevitably leads to End-Stage Kidney Disease (ESKD).
For decades, the standard of care (SoC) for CKD was largely limited to hemodynamic management using RAS inhibitors (ACEi or ARBs) to control blood pressure and reduce proteinuria. Drugs directly targeting the underlying "fibrosis" and "inflammation" were glaringly absent. Through the 2020s the CKD treatment landscape underwent a dramatic paradigm shift, and as of 2026 "direct control of fibrosis and inflammation" is increasingly recognized as a key mechanistic axis being incorporated into clinical guidelines — added as a layer on top of the established backbone of RAS inhibition, SGLT2 inhibition, and blood-pressure / proteinuria control.
This report comprehensively analyzes the recent clinical breakthroughs (including the FLOW and FINE-ONE trials) and the preclinical anti-inflammatory/antifibrotic mechanisms of the three therapeutic pillars redefining CKD treatment over 2023-2026: Finerenone (nsMRA), SGLT2 inhibitors, and GLP-1 receptor agonists. We also cover the newly approved 2025-2026 agents—Atrasentan, Sibeprenlimab, Iptacopan (C3G)—and next-generation pipelines currently in Phase 2/3 clinical trials—Aldosterone Synthase Inhibitors (ASIs), Endothelin Receptor Antagonists (ERAs), and Complement Pathway Inhibitors.
1.1 Conventional Standard of Care (SoC) and Its Limitations
For decades, the bedrock of CKD pharmacotherapy has been RAS inhibitors (ACEi or ARBs). While they reduce intraglomerular pressure and proteinuria, they carry significant limitations:
- No direct action on fibrosis: Once collagen has been deposited (fibrosis) or chronic inflammation has set in, RAS inhibitors have limited disease-modifying capability to reverse or halt these processes.
- Incomplete protection: RAS inhibitors alone cannot fully arrest CKD progression in many patients, and a significant proportion still progress to ESKD.
It is precisely this unmet medical need that catalyzed the emergence of the three therapeutic pillars described below, as well as the next-generation pipeline compounds now advancing through clinical trials.
2. The Three Key Drivers of Antifibrotic Kidney Protection
These three drug classes are moving beyond "symptom management" into the realm of disease modification, actively slowing the structural deterioration (fibrosis) of the kidneys.
2.1 Finerenone: Non-steroidal Mineralocorticoid Receptor Antagonist (MRA)
- Brand: Kerendia (Bayer)
Overactivation of the Mineralocorticoid Receptor (MR) directly drives inflammation and fibrosis in the kidneys and heart. While older steroidal MRAs (like spironolactone) carried high risks of hyperkalemia and endocrine side effects, the non-steroidal Finerenone offers high MR selectivity with a significantly improved safety profile.
[Clinical Breakthrough: Recent Developments] Finerenone is already approved to mitigate CKD progression in patients with Type 2 Diabetes (T2D) based on the FIDELIO-DKD1 and FIGARO-DKD2 trials. A major inflection point came with the Phase 3 FINE-ONE trial3 (242 patients, 80+ sites across 9 countries) presented at ASN Kidney Week 2025 (November 2025). Finerenone 10/20 mg significantly reduced the urine albumin-to-creatinine ratio (UACR) by 25% versus placebo at 6 months in patients with CKD associated with Type 1 Diabetes (T1D)—a population that had seen almost no therapeutic advancement in decades. Hyperkalemia incidence was 10.1% (vs 3.3% placebo). Bayer has announced plans to file an sNDA (supplemental NDA) with the FDA, with T1D label expansion anticipated from 2026 onward.
[Preclinical Mechanism: Direct Antifibrotic Action] Finerenone exerts clear renal protection independent of blood pressure lowering. In preclinical models of renal fibrosis such as Unilateral Ureteral Obstruction (UUO), finerenone has been proven to profoundly suppress macrophage infiltration and block the production of pro-fibrotic cytokines (e.g., TGF-β), thereby directly preventing glomerular and interstitial collagen deposition.
[Safety Considerations] The primary adverse effect of finerenone is hyperkalemia, requiring regular serum K+ monitoring. Notably, when co-administered with SGLT2 inhibitors, the risk of hyperkalemia appears to be somewhat mitigated compared to finerenone monotherapy.
2.2 SGLT2 Inhibitors (SGLT2i)
- Examples: Dapagliflozin (Farxiga), Empagliflozin (Jardiance)
Originally introduced solely as glucose-lowering agents for T2D, SGLT2 inhibitors are now foundationally recommended as first-line therapy to slow CKD progression "irrespective of diabetes status" (KDIGO 2024 Guidelines), following the landmark successes of DAPA-CKD4 and EMPA-KIDNEY5.
[Preclinical Mechanism: The Metabolism-Fibrosis Link] The renoprotective mechanisms of SGLT2i are remarkably multifaceted:
- Lowering Intraglomerular Pressure: They restore tubuloglomerular feedback (TGF), correcting glomerular hyperfiltration and alleviating mechanical damage.
- Suppression of Pro-fibrotic Signaling: SGLT2i have been shown to directly inhibit the canonical TGF-β/Smad signaling pathway.
- Senotherapeutic Effects: Insights accumulated over 2024-2026 reveal that SGLT2i combat cellular senescence and oxidative stress in renal tubular cells, thereby halting the epithelial-to-mesenchymal transition (EMT) that drives fibroblast accumulation.
2.3 GLP-1 Receptor Agonists (GLP-1RA)
- Examples: Semaglutide (Ozempic/Wegovy)
Famous for dramatic weight-loss and potent glycemic control, GLP-1RAs are now demonstrating independent, profound renoprotective properties.
[Clinical Breakthrough: The FLOW Trial] In the landmark 2024 Phase 3 FLOW trial6, semaglutide (1.0 mg) significantly reduced the risk of major kidney outcomes (including progression to kidney failure or halving of eGFR) by 24% compared to placebo in CKD patients with T2D. This definitively established GLP-1RAs not just as metabolic agents, but as primary "renal therapeutics."
[Preclinical Mechanism: Masters of Anti-Inflammation] GLP-1 receptors are expressed on immune cells as well as in the kidney. GLP-1RAs powerfully reduce oxidative stress and inhibit major inflammatory cascades, including the NF-κB pathway. Because persistent local inflammation in the renal microenvironment is the primary trigger for fibrosis (collagen deposition), this robust anti-inflammatory action acts upstream to ultimately delay the progression of renal fibrosis.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. Next-Generation Pipeline Compounds (Phase 2/3)
While the three established pillars are consolidating their roles, a new wave of compounds with distinct mechanisms of action are advancing rapidly through clinical trials targeting renal fibrosis.
3.1 Aldosterone Synthase Inhibitors (ASIs)
Unlike Finerenone (which blocks the receptor), ASIs inhibit the production of aldosterone itself at the enzyme level. This approach minimizes off-target effects on cortisol signaling while effectively controlling MR overactivation.
| Compound | Developer | Phase | Key Trial & Results |
|---|---|---|---|
| Baxdrostat | AstraZeneca | Phase 3 | Phase 3 trial with dapagliflozin in CKD + hypertension (NCT06268873, 24-month double-blind) is ongoing8. In 2025, Baxdrostat monotherapy Phase 3 trials in hypertension (BaxHTN, Bax24) met primary endpoints (systolic BP reduction of 14.0 mmHg), providing supportive data |
| Lorundrostat | Mineralys Therapeutics | NDA Accepted | Explore-CKD trial9: Achieved significant reductions in SBP and UACR in CKD + hypertension. NDA submitted end of 2025; FDA accepted the NDA in March 2026 (hypertension indication), PDUFA date December 22, 2026 (CKD indication under continued development) |
| Vicadrostat (BI 690517) | Boehringer Ingelheim | Phase 3 | Phase 2: UACR reduced by up to 39.5% with empagliflozin10. Phase 3 EASi-KIDNEY trial (NCT06531824, ~11,000 patients, 15-20 countries, 3.0-year median follow-up) is underway. Primary endpoint readout expected 2027 or later |
3.2 Endothelin Receptor Antagonists (ERAs)
Endothelin-1 (ET-1) is a potent vasoconstrictor that also directly promotes mesangial cell proliferation and collagen deposition, driving renal fibrosis. ERAs block this pathway, but historically fluid retention was a limiting side effect. The current paradigm combines ERAs with SGLT2 inhibitors to offset this risk.
| Compound | Developer | Phase | Key Trial & Results |
|---|---|---|---|
| Atrasentan (Vanrafia) | Novartis | Approved (transitioning to full) | FDA Accelerated Approval in April 2025 (Vanrafia, IgA nephropathy). ALIGN trial final analysis at Week 136, presented February 202611, demonstrated significant eGFR decline slowing (+2.39 mL/min/1.73m² vs placebo); transition to traditional approval is underway |
| Sparsentan (Filspari) | Travere Therapeutics | Approved (multiple indications) | Dual ET/AT1 antagonist. FDA full approval for IgA nephropathy in September 2024, followed by FDA approval for FSGS on April 13, 2026—the first approved therapy for FSGS, based on DUPLEX/DUET data (original PDUFA of January 2026 was extended during review)12 |
| Zibotentan + Dapagliflozin | AstraZeneca | Phase 3 | ZENITH-CKD (Phase 2b): UACR reduction of -33.7% vs dapagliflozin alone at 12 weeks. Phase 3 ZENITH High Proteinuria trial13 is ongoing; no topline results as of April 2026 |
3.3 Complement Pathway Inhibitors
In diseases such as IgA nephropathy and C3 glomerulopathy, where aberrant immune activation drives fibrosis, complement cascade inhibition has proven effective. Multiple agents are now approved or nearing approval.
| Compound | Developer | Phase | Key Trial & Results |
|---|---|---|---|
| Iptacopan (Fabhalta) | Novartis | Approved (traditional sNDA planned) | Factor B inhibitor. FDA Accelerated Approval for IgA nephropathy in August 2024 (APPLAUSE-IgAN interim analysis showed 38.3% proteinuria reduction14). C3 glomerulopathy approval on March 20, 2025—the first-ever therapy for C3G. APPLAUSE-IgAN 24-month final analysis (announced March 29, 2026; NEJM 2026) showed 49.3% slowing of eGFR annual decline vs placebo; Novartis plans to submit the sNDA for traditional approval during 2026 |
| Sibeprenlimab (Voyxact) | Otsuka / Visterra | Accelerated Approval | Anti-APRIL antibody (4-weekly subcutaneous). FDA Accelerated Approval granted November 25, 2025 for IgA nephropathy. VISIONARY Phase 315 (n=530) 9-month prespecified interim showed 51.2% proteinuria reduction vs placebo (between-group difference, 95% CI −58.2 to −42.9) |
4. The Future Standard: Layered Combination Therapy
The KDIGO 2024 CKD Guidelines (the most recent CKD-wide guideline; KDIGO 2025 ADPKD and IgAN/IgAV guidelines were separately published in 2025) and the 2026 ADA Standards of Care (Section 11: Chronic Kidney Disease and Risk Management)16 now advocate for a "Layered Therapeutic Strategy" incorporating these agents. Drawing on recent evidence such as the CONFIDENCE trial, ADA 2026 outlines an approach in which early initiation of both an SGLT2 inhibitor and a non-steroidal MRA — often simultaneously, or in close sequence — is favored for T2D-CKD patients with UACR ≥30 mg/g, eGFR within acceptable range (commonly ≥25 mL/min/1.73 m²), and serum potassium within an acceptable range (typically ≤4.8 mEq/L) before non-steroidal MRA initiation. Exact thresholds and patient-level decisions should be drawn from the primary text (Diabetes Care 2026;49(Suppl 1), Section 11):
- Foundation: RAS inhibitors (ACEi/ARB) for hemodynamic control.
- Layer 1: SGLT2 inhibitors to correct intraglomerular pressure and metabolic stress.
- Layer 2: GLP-1RAs (for robust inflammatory and weight control) or Finerenone (to block MR-driven direct fibrosis).
- Future Layers: Potential addition of ASIs (aldosterone production blockade) or ERAs (endothelin pathway interruption), creating "quadruple" or "quintuple" therapy.
The Phase 2 CONFIDENCE trial7, published in the New England Journal of Medicine in June 2025, demonstrated that simultaneous initiation of finerenone and an SGLT2 inhibitor (empagliflozin) achieved a 52% reduction in UACR (+29% vs finerenone alone, +32% vs empagliflozin alone), providing robust evidence for the effectiveness of the layered approach.
5. Translation to Preclinical Animal Models
These clinical paradigm shifts heavily influence how novel drug candidates must be tested in preclinical environments.
- UUO (Unilateral Ureteral Obstruction) Model: The gold standard for rapidly evaluating the transition from severe inflammation to aggressive tubulointerstitial fibrosis. It is ideal for screening the direct antifibrotic and anti-inflammatory mechanisms of drugs akin to Finerenone.
- Adenine-Induced CKD / Alport Syndrome Models: Models featuring progressive glomerulosclerosis and eGFR decline over weeks to months. These are critical for evaluating the long-term, functional renoprotective effects of SGLT2i and combination therapies.
- MASH/NASH Comorbid Models (e.g., GAN diet): Models that replicate the modern patient phenotype—featuring obesity, met-dysfunction, liver fibrosis, and diabetic nephropathy. These are becoming indispensable for evaluating the multi-organ protective effects of novel incretins (GLP-1/GIP/Glucagon multi-agonists).
6. Conclusion
By 2026, the frontier of CKD treatment has unequivocally shifted toward the strict control of "inflammation and fibrosis." Armed with Finerenone, SGLT2 inhibitors, and GLP-1RAs—three distinct but complementary weapons—and with the 2025 Accelerated Approval of Atrasentan (Vanrafia), the C3G approval of Iptacopan, the November 2025 approval of Sibeprenlimab (Voyxact) for IgAN, and the April 2026 FSGS approval of Sparsentan (Filspari), a cascade of next-generation therapies has entered routine clinical practice. With Lorundrostat NDA acceptance (PDUFA December 22, 2026) and the ongoing EASi-KIDNEY trial of Vicadrostat, further approval waves are anticipated in 2027 and beyond. Long-term stabilization of renal function through multi-layered pharmacological intervention is now a widespread reality.
For developers of next-generation antifibrotic therapies, the critical challenge ahead will no longer be beating a placebo, but conclusively demonstrating a statistically significant add-on effect on top of this highly effective, multi-layered new standard of care.
Related Preclinical Models
Start with our Renal Fibrosis Models — UUO, adriamycin & folic acid protocols for CKD endpoint selection.
References & Clinical Trial Information
Finerenone (nsMRA)
1. Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-2229. (FIDELIO-DKD: NCT02540993)
2. Pitt B, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385:2252-2263. (FIGARO-DKD: NCT02545049)
3. Bayer. FINE-ONE Topline Results: Finerenone in CKD Associated with Type 1 Diabetes. Presented at ASN Kidney Week 2025 (November 2025). (NCT05901831)
SGLT2 Inhibitors
4. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-1446. (DAPA-CKD: NCT03036150)
5. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117-127. (NCT03594110)
GLP-1 Receptor Agonists
6. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109-121. (FLOW: NCT03819153)
Combination Therapy
7. Agarwal R, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-543. (CONFIDENCE: NCT05254002)
Aldosterone Synthase Inhibitors (ASIs)
8. Baxdrostat + Dapagliflozin Phase 3: NCT06268873
9. Lorundrostat Explore-CKD Phase 2: NCT06150924
10. Tuttle KR, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403:379-390. Phase 3 EASi-KIDNEY: NCT06531824
Endothelin Receptor Antagonists (ERAs)
11. Atrasentan ALIGN Phase 3 (IgA Nephropathy): NCT04573478 — FDA Accelerated Approval: April 2025 (Vanrafia); Week 136 final analysis: February 2026.
12. Sparsentan (Filspari) — FDA Full Approval for IgA Nephropathy (September 2024), FSGS indication approval on April 13, 2026 (original PDUFA of January 2026 was extended during review). Phase 3 DUPLEX (FSGS) / PROTECT (IgAN).
13. Zibotentan + Dapagliflozin ZENITH High Proteinuria Phase 3: NCT06087835
Complement Pathway Inhibitors
14. Iptacopan APPLAUSE-IgAN Phase 3: NCT04578834 — IgAN Accelerated Approval: August 8, 2024; C3G Approval: March 20, 2025. APPLAUSE-IgAN 24-month final analysis announced March 29, 2026 (2026 World Congress of Nephrology; NEJM 2026), showing 49.3% slowing of eGFR annual decline vs placebo.
15. Sibeprenlimab VISIONARY Phase 3: NCT05248646 — FDA Accelerated Approval: November 25, 2025 (Voyxact).
16. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). (Integrates recent evidence such as the CONFIDENCE trial to frame early co-initiation of SGLT2 inhibitors and non-steroidal MRAs; consult the primary text for eGFR / potassium thresholds and patient-level decisions.)
Related Articles
Individual Drug Deep-Dives
- Finerenone (Kerendia): nsMRA for DKD/HFpEF
- Iptacopan (Fabhalta): Factor B Inhibitor for IgAN/PNH/C3G
- Sibeprenlimab (Voyxact): anti-APRIL FDA Accelerated for IgAN
- Atrasentan (Vanrafia): ETA-Selective Antagonist for IgAN
- Inaxaplin (VX-147): APOL1 Channel Inhibitor for AMKD
- Atacicept: BAFF+APRIL Dual Inhibitor for IgAN Phase 3
- Sparsentan (Filspari): First FSGS Approval